Please login to the form below

Not currently logged in
Email:
Password:

Vintura appoints Lieven Annemans as an associate partner

He will advise the consultancy's clients on market access issues

Lieven AnnemansHealthcare and life sciences consultancy firm Vintura has appointed health-economics professor Lieven Annemans as an associate partner after previously working with him in health-economic areas.

His new role will see him advise international life sciences organisations with market access challenges.

Bas Amesz, partner at Vintura, said: “Lieven adds valuable knowledge and international experience in the areas of health-economics and value-based healthcare.

“Furthermore, Lieven is also a valuable addition to our team, he is an inspiring ‘thought leader’ with a no-nonsense work ethic and a pleasure to work with.”

The professor teaches in the faculty of medicine and health sciences at Ghent University based in Belgium and he is also president of the Flemish Healthcare council.

“By joining forces with Lieven we will increase our ability to create meaningful impact in healthcare by advising and supporting healthcare organisations, industry and government.

“This way we will jointly contribute to the realisation of universal and equitable access of patients to new therapies.”

Annemans has served in a variety of roles including president of the Internation Society for Pharmaeconomics and Outcomes Research (ISPOR), former cabinet advisor to secetary Frank Vandenbroucke and is the laureate of the Francqui chair in 2013 and 2016.

10th July 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics